Trevogrumab Phase 2 Lean Mass Signal Is Real But Surrogate-Only — Approval Path Uncharted

COURAGE Trial Confirms Trevogrumab Preserves Muscle During Weight Loss

Regeneron Pharmaceuticals announced positive results from its Phase 2 COURAGE trial, evaluating trevogrumab (anti-GDF8/anti-myostatin) for preventing lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people with obesity. The trial demonstrated that trevogrumab significantly preserved lean mass at both 26 and 52 weeks compared to semaglutide alone. Specifically, the 75 mg dose preserved 50.7% of lean mass at 26 weeks and 42.5% at 52 weeks. An MRI substudy further confirmed approximately 70% muscle preservation. These findings were presented at the EASD Annual Meeting and are in press with The Lancet, supporting further clinical development.

• The COURAGE trial's primary endpoint showed that trevogrumab effectively preserved lean mass. At 26 weeks, the 25 mg dose preserved 29.9% and the 75 mg dose preserved 50.7% of lean mass relative to placebo + semaglutide. These benefits were sustained at 52 weeks, with 20.5% and 42.5% preservation for the respective doses, addressing a key concern with GLP-1 receptor agonist therapies.
• An MRI substudy provided further validation, demonstrating that trevogrumab preserved a substantial amount of thigh muscle. The lower doses of trevogrumab prevented almost 70% of the muscle loss that would have occurred with semaglutide treatment alone, with the 75 mg dose showing 72.7% preservation at 26 weeks and 68.9% at 52 weeks, highlighting its potential to improve the quality of weight loss.
• Trevogrumab was generally well tolerated, with 77% of participants experiencing at least one adverse event, compared to 82% in the placebo group. Common adverse events included nausea, constipation, diarrhea, and vomiting. Building on these results, Regeneron plans to initiate a new Phase 2 trial evaluating trevogrumab in combination with GLP-1 receptor agonists in older adults with obesity and decreased muscle mass or strength.

Addressing the Challenge of Muscle Loss in GLP-1 RA Therapy

Despite meaningful advances in pharmacological and surgical options, obesity treatment remains constrained by a convergence of biological, clinical, and systemic barriers. Long-term weight maintenance continues to pose the greatest challenge, driven by counter-regulatory physiological mechanisms that persist well beyond the initial period of weight loss.

• Metabolic adaptation and weight regain: Diet-induced and pharmacologically induced weight loss triggers compensatory reductions in total daily energy expenditure that exceed predictions based on body composition changes alone. Concurrent shifts in gut hormone profiles — including reduced anorectic hormone secretion and increased orexigenic hormone levels — amplify appetite and the reward value of food, creating a sustained biological drive toward weight recidivism that extends beyond patient motivation or adherence.

• Loss of fat-free mass with weight loss interventions: Both bariatric surgery and GLP-1 receptor agonists raise concerns about unintended loss of fat-free mass, particularly skeletal muscle. This loss compromises physical functionality, quality of life, and long-term metabolic health, with particular risk in individuals with sarcopenic obesity or those at risk of frailty. Current weight-loss strategies often fail to adequately address the need to maintain fat-free mass.

• Gastrointestinal adverse effects limiting adherence: GI side effects — predominantly nausea, vomiting, diarrhea, and constipation — are common across anti-obesity medications, particularly GLP-1 receptor agonists such as semaglutide and tirzepatide, especially during dose escalation. In randomized controlled trials, treatment discontinuation due to adverse events was significantly higher with semaglutide versus placebo (RR 2.62, 95% CI: 1.70–4.03; P = .001), underscoring the impact of tolerability on long-term outcomes.

• Access, cost, and insurance barriers: High costs, supply shortages, and unequal access pose significant barriers to widespread implementation of obesity treatment, particularly in low-resource settings. Insurance coverage gaps affect both pharmacological and surgical options — only 1% of the currently eligible population undergoes bariatric surgery in the United States, with roughly 228,000 individuals receiving it annually, partly attributable to restrictive insurance benefit design.

• Limitations specific to pediatric populations: Access to FDA-approved anti-obesity medications in patients under 18 years old is constrained by age restrictions, insurance coverage, and cost. Further studies are needed to evaluate the efficacy and long-term safety of both FDA-approved and off-label medications for obesity treatment in pediatric patients.

• Educational gaps and perception barriers: Both people with obesity and healthcare providers cite concerns regarding long-term side effects, costs, and a perception of anti-obesity medications that does not align with treatment of a chronic disease. These gaps impede shared decision-making and the adoption of recommended multimodal chronic care approaches.

COURAGE Trial Confirms Trevogrumab Preserves Muscle During Semaglutide Weight Loss

Recent meta-analyses and clinical studies have reinforced the efficacy of GLP-1 and dual incretin receptor agonists for weight management in adults with overweight or obesity, while also characterising their tolerability profiles. The evidence spans subcutaneous and oral formulations, head-to-head comparisons, and novel small-molecule agents, offering clinical and strategic teams a broad view of the evolving obesity pharmacotherapy landscape.

Optimizing Obesity Treatment: Trevogrumab's Promise for Muscle Preservation

The landscape of obesity management has been profoundly reshaped by the advent of GLP-1 receptor agonists, offering significant weight reduction. However, a critical challenge has emerged: a substantial portion of this weight loss, often exceeding 25%, comes from lean body mass, including vital skeletal muscle. This can lead to concerns about sarcopenia, impaired metabolic health, and reduced physical function, particularly for vulnerable populations like older adults. Addressing this, Regeneron's trevogrumab, an anti-myostatin antibody, has shown promising Phase 2 results from its COURAGE trial.

The trial demonstrated that trevogrumab significantly preserved lean mass during GLP-1 RA-induced weight loss, with over 50% preservation at 26 weeks and 42.5% at 52 weeks, and approximately 70% muscle preservation confirmed by MRI. These findings are pivotal, suggesting a potential paradigm shift in how obesity is treated. Instead of solely focusing on weight reduction, future strategies could prioritize optimizing body composition, ensuring healthier and more sustainable weight loss.

This development carries significant strategic implications. Trevogrumab could establish a new standard for obesity treatment, positioning Regeneron as a leader in a rapidly expanding market by offering a differentiated solution that mitigates a key drawback of current therapies. It also paves the way for a new class of 'body composition optimizers' designed to be co-prescribed with weight loss medications, creating a valuable new segment within metabolic health.

However, several risks must be carefully considered. While promising, these are Phase 2 data, and the long-term efficacy and durability of lean mass preservation, especially its impact on functional outcomes, require confirmation in larger, longer Phase 3 trials. The safety profile of trevogrumab in combination with GLP-1 RAs also needs thorough evaluation. Furthermore, the added cost of a combination therapy will necessitate robust evidence of cost-effectiveness and significant clinical benefits to ensure broad payer acceptance and patient access. Ultimately, if successful, trevogrumab could transform obesity management, offering a path to not just weight loss, but healthier, more functional weight loss, thereby improving long-term patient well-being.